Cannabis
What We Know of Germany’s New Cannabis Plans
Germany has sure been through the ringer. In a single year it went from charging forth with a full cannabis legalization, to going back on nearly everything it said; and scaling back all plans. It certainly isn’t what was initially hoped for, but here’s a look at Germany’s new cannabis plans, recently released as a draft bill.
Germany’s new cannabis plans
First and foremost, anytime you hear about a ‘draft law’ it means its not a real law, or at least, not yet. A draft is a rough copy. In the case of politics, its sort of like a hope. Some draft laws pass through houses of legislation quickly without edits; and some get torn apart, rewritten, or thrown out all together. So in terms of Germany’s new cannabis plans, they’re certainly not concrete, and represent what the country is trying for, but not what will definitely happen.
As per MJBizDaily, the new draft law also only covers part of what Germany wants to do with its scaled-back weed industry. The second half, not gone into here, involves a pilot program with very limited sales access. We’ll find out more about that later. In the first week of July, Germany released its tentative plans for the first part of the legalization; which include cultivation, both privately, and by groups. This is the current draft law.
Personal cultivation is a little easier. The real meat of the draft law has to do with what it calls ‘cultivation associations;’ not-for-profit groups that can grow cannabis for members, and then give it out to them. The members pay a fee to be in the club, and this fee covers their use; so there are no direct sales. This keeps it from being a standard sales market, as no specific product is paid for directly.
It’s essentially a government loophole, that gets around another government law. The EU won’t allow sales markets, these associations get around that. It’s the same loophole that Spain made famous with its cannabis social clubs. Unlike Spain’s setup, Germany’s associations will be for dissemination only, and will not be a place for social smoking.
The draft goes over certain points, some of which have already been discussed. All are related to personal cultivation and associations. Here are a few of the main ones:
- Each person can grow up to three plants
- Legal possession limit – 25 grams for adults
- Association limits for dissemination – 25 grams per a day, or 50 grams in a month
- Those under 21 cannot grow or access products with more than 10% THC
- Those under 21 cannot access more than 30 grams a month
- Neither cannabis, nor the associations that grow it, can be advertised or sponsored
What happens next?
A draft either passes into new law, or doesn’t. In order for this draft bill to pass, it has to get through a few steps. By mid-August its expected the current draft will go before the Cabinet. Assuming it gets past the cabinet, it moves onto both the parliament (Bundestag), as well as Bundesrat; a federal body which represents all 16 states in the country. It is up to the Bundestag to make the final decision in the end. Should that happen in a timely manner, its expected the legislation could go into effect by the end of this year.
This draft law is only one half of Germany’s new cannabis plans. Part of the upcoming process, is the introduction of legislation for the second half; the pilot program. As stated, this program will allow some amount of a limited sales market, although how limited is still not known. A pilot study is just an investigation into something on a small-scale, to determine how it could work on a bigger scale. So the idea is to investigate how a full-scale recreational legalization would work, by testing it on a smaller segment of the population.
This part is the part that overlaps more with EU policy. The part that must get a formal go-ahead. As per Germany, this part will be drafted in conjunction with the European Commission, as well as the other EU member states. Simply accepting that it can’t be a regular sales market is not enough. As recreational sales are involved, it requires a higher level of approval, from outside of Germany.
Nothing like this exists yet in the EU. Lets remember Switzerland and its pilot program are not a part of the EU, and not subject to EU laws when it comes to cannabis. As far as Luxembourg and Malta, the other two EU countries to pass legalization measures; neither attempted any kind of sales market, not even in the form of a pilot study. Malta’s legalization involves associations, but Luxembourg’s is just about cultivation.
Germany had such big plans
This issue of the EU and needing to follow its policy, is certainly adding some difficulty to cannabis reform measures that cross the line into recreational sales markets. The EU is okay with medical sales markets, and the majority of EU countries have them. Realistically, the EU as a federal body, does have its own concerns; like deals with other countries, and membership in international drug conventions. It’s the parent to its member-state children, and holds the ability to say ‘no.’
We saw this very distinctly with Germany. Germany decided over a year ago to legalize cannabis, but didn’t give details at the time as to how. By last fall, the word was out that the country was going to fully legalize cannabis, and open a recreational sales market. It was supposed to happen by spring of 2023.
It wasn’t until early 2023 that the whispers of problems became more like a roar. The previously ignored concept that the EU would have to approve, became a complete reality. While some politicians wanted to fight it, Health Minister Karl Lauterbach did not. In the end, when the announcement came after Easter, there was no sales market in the picture. Germany officials never explained fully what the EU said, but it was understood, that the governing body had not approved.
The same concept affected Luxembourg, although that country never tried like Germany did. It mentioned legalizing a few years ago, but only officially passed the measure last month. It had also originally planned a full scale sales market.
It ended up only passing a personal cultivation law; sans associations, and sans personal use amounts above a few grams; making it very much not a law that encourages anything outside of one’s house. While it could be that not the whole country was onboard with a sales market, its more likely that Luxembourg did this to evade issues with the EU.
Cannabis reform and the EU
The thing is, the EU can’t do this forever. Whatever reasons it has, eventually must be ironed out. This seems to be understood in that the EU recently held its first ever debates on cannabis. Called ‘Legalization of Personal Use of Cannabis: Exchange of Best Practices,’ it was chaired by Ireland’s Luke Flanagan, who had this to say:
“The importance of this gathering is not so much what we can get the European Commission to do, it’s more to see that they don’t get in the way and hinder this process. We don’t have competence over this area but it seems the Commission has the power to throw spanners in the spokes when countries try to do it.”
The co-chair to the meeting was the Czech Republic’s Mikuláš Peksa. The Czech Republic is looking to pass its own legalization measure, and has been extremely quiet about what it plans to do; probably because its still not sure how hard it can push. There are implications that the country wants to open a full sales market; but its unclear what exactly this means, or how the country will deal with the EU, if this is the intention. What is for sure, is that the Czech Republic knows its got an issue on its hands.
Legalization co-drafter Tomas Sadilek explained, “The European Commission is our biggest obstacle… it is always easier to regulate than deregulate and withdrawing cannabis from European legislation is very problematic.” He broke the problem down into three issues; general Schengen laws, EU drug trafficking laws from 2004, and international drug conventions.
Conclusion
Germany’s cannabis plans for personal cultivation and associations should pass through, although there could be an editing process. But this is a far cry from what the country originally wanted; and is representative of the main issue that stops recreational sales markets in the EU.
Welcome cannabis supporters! Cool that you’re here with us at Cannadelics.com, where we work daily to bring you the best in drugs reporting, with an emphasis on the cannabis and hallucinogen spaces. Check out our updates regularly to stay current; and get subscribed to the Cannadelics Weekly Newsletter, for awesome promos, along with the news.
Related
The federal administration is all over the board around fed cannabis policy…and millions of patients are worried.
The industry employees over 440,000 workers at all lives and is driven in a large part by mom and pop businesses. Millions use medical marijuana for health issues ranging from chronic pain to sleep. But there are mixed messages from the feds about cannabis, and people are very worried. The federal government’s stance on marijuana has become increasingly complex, as recent developments show conflicting approaches to the drug’s potential benefits and risks. On one hand, there’s a push for research into medical marijuana for veterans, while on the other, a campaign against cannabis use is being launched.
RELATED: Music Is A Turn On Like Sex And Marijuana
The juxtaposition of initiatives highlights the federal government’s inconsistent approach to marijuana policy. While some departments are exploring the potential benefits of cannabis, others are actively working to discourage its use. This dichotomy is further exemplified by ongoing legislative efforts. For instance, Rep. Brian Mast (R-FL) has reintroduced the Veterans Equal Access Act, which would allow VA doctors to recommend medical marijuana to patients in states where it’s legal. Meanwhile, documents from an ongoing lawsuit suggest that the DEA may have weighted the marijuana rescheduling process to ensure rejection of moving the drug from Schedule 1 to Schedule 3.
The Department of Defense (DOD) has allocated nearly $10 million in funding for research into the therapeutic potential of MDMA for active-duty military members. This initiative, driven by congressional efforts, aims to explore MDMA’s effectiveness in treating conditions such as post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Rep. Morgan Luttrell (R-TX) expressed pride in this development, stating that it could be a “game-changer” for service members battling these combat-related injuries.
Additionally, a bipartisan effort in Congress has been pushing for VA research on medical marijuana for PTSD and other conditions affecting veterans. The VA Medicinal Cannabis Research Act, introduced in both the Senate and House, would mandate studies on how cannabis affects the use of addictive medications and impacts various health outcomes for veterans.
RELATED: The Science Behind Why Music Sounds So Much Better When You’re High
In stark contrast to these research initiatives, the Drug Enforcement Administration (DEA) has partnered with an anti-cannabis nonprofit to launch a social media campaign targeting young people. The campaign, set to run ahead of April 20 (4/20), aims to “flood” Instagram with anti-cannabis content. The DEA is offering monetary incentives to students for creating and posting anti-THC videos, with payments ranging from $25 to $50 depending on the type of content produced.
This approach has raised eyebrows, as it seems to contradict the growing acceptance and legalization of marijuana across the United States. Critics argue that such campaigns may be out of touch with current societal trends and scientific understanding of cannabis.
Not everyone has access to marijuana to help them sleep – good news, hemp is available.
RELATED: Mike Johnson And Marijuana
Hemp contains several compounds contributing to better sleep quality. Cannabidiol (CBD), a non-psychoactive component of hemp, has shown potential in promoting relaxation and reducing anxiety, which can often interfere with a good night’s rest. Studies suggest that CBD may help individuals fall asleep faster and experience fewer sleep disturbances throughout the night.
When formulated and used properly, preliminary research and user reports suggest that hemp gummies improve subjective sleep quality. Users of quality hemp sleep gummies report feeling more rested, a better quality of sleep and fewer awakenings in the night. However, clinical research has shown that over consumption of THC negatively impacts the quality of sleep, especially with long term use.
Wana Brands has launched a hemp sleeping product nationally, Mike Hennesy, Vice President of Innovation shared the following about how it works. Naturally hemp-derived sleep gummies contain the same cannabinoids like CBD, CBN, and THC as cannabis or marijuana. These ingredients interact with receptors in the body’s endocannabinoid system, which plays a role in regulating mood, stress, and sleep-wake cycles. For example, CBD may promote relaxation and reduce anxiety, CBN can relieve discomfort and reduce awakenings, while THC can shorten the time it takes to fall asleep, especially at low doses. Together, they may help ease the mind and body into a sleep-ready state.
The best sleep products don’t rely on just one cannabinoid like CBN but instead use a combination of cannabinoids, terpenes, and other sleep-supporting ingredients such as melatonin. This is because the reasons for sleeplessness are multifaceted, and include trouble falling asleep, staying asleep, chronic, pain and anxiety. Each ingredient targets different root causes as well as synergizes with the other cannabinoids and terpenes for the best night sleep.
Longer lasting formulations can actually help reduce awakenings in the night. CBN has been shown in recent research to reduce the number of times you wake up in the night. Combined with other cannabinoids they can synergize to reduce discomfort and anxiety helping consumers stay asleep.
RELATED: Marijuana Use And Guy’s Member
If you do wake up in the middle of the night and can’t fall back asleep products including CBD and CBG to reduce middle of the night anxiety and racing thoughts that can keep us awake, and they have only 1mg of THC so you wake up refreshed and not high in the morning.
For most people, hemp-derived cannabinoids are considered safe and non-intoxicating, with a low risk of dependence. When THC is included in small amounts, it can produce mild effects and can help us fall asleep faster. It generally poses a minimal risk when used in moderation, but there is a potential for dependence if overused, just like with any sleep aid. Adverse events are far more prevalent in pharmaceutical and even over the counter sleep aids than with hemp-derived cannabinoids.
The key is responsible use, including starting with a low dose and taking breaks when needed. If you rely on it every night at high doses, your body may adjust, and it can be habitual. But when used in moderation and with a well-balanced formula, cannabis can be a sustainable part of a healthy sleep routine.
Alcohol has some negative side effects, but cannabis could have one positive health benefit – it might help your good cholesterol.
In the late 1980s cholesterol test became come as the impact of it on the body and heart was becoming more evident. Research shows good cholesterol (HDL) helps remove excess cholesterol from the body, while “bad” cholesterol (LDL) can build up in arteries, potentially leading to heart disease. Alcohol and tobacco are known to be rough on the body, but can marijuana help cholesterol?
RELATED: Could Medical Marijuana Help Pope Francis
Marijuana’s potential impact on cholesterol is an emerging area of research, offering both promising insights and areas for further exploration. While studies have yet to reach definitive conclusions, evidence suggests that cannabis may influence cholesterol levels in ways that could benefit cardiovascular health under certain conditions.
Cannabis contains cannabinoids like THC and CBD, which interact with the body’s endocannabinoid system. This system plays a role in regulating various physiological processes, including lipid metabolism. Some studies have indicated that marijuana use might improve cholesterol profiles by increasing high-density lipoprotein (HDL), commonly known as “good cholesterol.” For instance, research published in BMJ Open found that marijuana users had elevated levels of HDL cholesterol, which is associated with better cardiovascular health.
Moreover, cannabis has demonstrated anti-inflammatory properties and the ability to regulate blood glucose levels. These effects can indirectly support heart health by reducing risk factors associated with high cholesterol, such as diabetes and obesity. Additionally, cannabinoids like CBD may help protect the heart from oxidative stress and inflammation, further enhancing cardiovascular health.
RELATED: The Science Behind Why Music Sounds So Much Better When You’re High
Cannabis has also been linked to weight management benefits, which can positively impact cholesterol levels. Studies have shown that marijuana use may reduce abdominal fat and improve metabolic parameters. Since obesity is a major contributor to high LDL cholesterol levels, these findings suggest that cannabis could play a supportive role in maintaining healthy cholesterol levels.
While some studies highlight potential benefits of cannabis for cholesterol and heart health, others caution against its risks. Daily marijuana use has been associated with an increased risk of heart failure and other cardiovascular issues. However, research also indicates that cannabis may reduce the risk of atrial fibrillation and improve outcomes following heart attacks.
The best energizing THC gummies of 2025 by Leafly
Mixed Messages From The Feds About Cannabis
How Hemp Helps You Sleep
420 in Texas is at Reggie & Dro
Daily Cannabis Use Can Help People Get Off Opioids (STUDY)
This Wine Issue Is Becoming More Common
Get more for less this 420 at PurLife
Can You Order Cannabis through DoorDash?
Cannabis Enthusiast-Friendy Retreats – GanjaVacations Jamaica
The road ahead for cannabis lending in 2025
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
-
Cannabis News2 years agoDistressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years agoUnited States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years agoWhat you Need to Know
-
drug testing1 year agoDrug Testing for Marijuana – The Joint Blog
-
Education2 years agoNCIA Write About Their Equity Scholarship Program
-
Cannabis2 years agoIt has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years agoCannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years agoA new April 20 cannabis contest includes a $40,000 purse